Understanding Juvenile Idiopathic Arthritis and Its Coverage Under Medical Schemes in South Africa

By Danélia Botes

September 4, 2023

Juvenile Idiopathic Arthritis (JIA) is an autoimmune disease where the body’s immune system mistakenly attacks its own healthy cells and tissues, leading to inflammation in the joint membrane or the synovial membrane. This condition is the most prevalent type of arthritis in children under the age of 16.

JIA is included in the Chronic Disease List (CDL) of the Prescribed Minimum Benefit (PMB) regulations under Rheumatoid Arthritis in South Africa. This means that medical schemes are obligated to fully fund the diagnosis, treatment, and care costs of this condition, according to the Council for Medical Schemes (CMS). However, the treatment guidelines for JIA reference the algorithm for Rheumatoid Arthritis for adults, which can differ significantly from the needs of children with JIA.

With JIA, an alternative paediatric clinical management protocol must be included within this benefit if it is supported by evidence-based medicine, considering cost-effectiveness and affordability. Sources to use include the American Academy of Orthopaedic Surgeons, Arthritis Kids South Africa, Johns Hopkins Medicine, Mayo Clinic, Medline Plus and National Institutes of Health.

Medical schemes may use medicine formularies – a list of specific medicine for the treatment of the condition. Therefore, it’s crucial to check with the medical scheme which medicines are included in the medicine formularies to avoid a co-payment on the chronic medication. If a member or beneficiary of a medical scheme chooses to use medicines not on the formulary, a co-payment on the treatment may be applied. This update from the CMS does not include specific information regarding the use of biologics in JIA.

Medical schemes are also allowed to put in place baskets of care that allow for a specific number of consultations, blood tests and other tests to monitor the condition. However, when care outside of the normal basket is required, the medical scheme cannot completely refuse to fund it. The treating doctor should send a letter of motivation to the medical scheme indicating the required care and the reasons. If clinically appropriate, the medical scheme must fund it as PMB.

Reference url

Recent Posts

Cutaneous Malignant Melanoma Treatment

Forecasting Innovations in Cutaneous Malignant Melanoma Treatment in Sweden

“Shaping Melanoma Care: Insights for UV Safety Month”

🌟 Exciting Insights! Learn how system dynamics modelling shapes the future of cutaneous malignant melanoma care during UV Safety Month. Discover key strategies for better healthcare planning and patient outcomes. #SyenzaNews #UVSafetyMonth #HealthcarePlanning #MelanomaCare #PreventiveInterventions 🏥

skin cancer primary prevention

Enhancing Skin Cancer Prevention in a Primary Care Setting

🌞 Discover the latest strategies in skin cancer primary prevention! From innovative risk assessment tools to new technologies, learn how primary care can play a pivotal role in reducing skin cancer rates.
🩺👩‍⚕️👨‍⚕️ #SyenzaNews #Healthcare #SkinCancerPrevention #PrimaryCare #Innovation

Valvular heart disease in Saudi Arabia

Addressing Valvular Heart Disease in Saudi Arabia

#SyenzaNews 🚀 Valvular heart disease (VHD) is a growing concern in Saudi Arabia, especially among the ageing population.
Discover the current challenges and actionable recommendations to enhance VHD care.

Let’s work together to improve awareness, detection, and treatment! #Healthcare #Cardiology #SaudiArabia #HealthyAging 🌟

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.